ClinicalTrials.gg
CompletedNCT06067230Updated Aug 20, 2026

A Study to Investigate the Immunogenicity and Safety of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in High-risk Adults

A Phase 3 interventional study of mRNA-1345 in Respiratory Syncytial Virus, sponsored by ModernaTX, Inc.. Completed at 44 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,153
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases — none open to participants now, none under way, none of them phase 3. mRNA-1345 respiratory syncytial virus vaccine · Virus Diseases.

Enrollment
4th of 10
1,153 · median 579
Started
2023
with 3 others
Phase 3
4 of 10
none open now
Registered
7th of 10
by date
Lead sponsor
10 of 10
ModernaTX, Inc.

Among the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases, this one is the 4th largest by enrollment, is one of 4 that started in 2023, is one of 4 in phase 3, and was the 7th registered.

Virus Diseases

656 studies on the registry are indexed under Virus Diseases; 83 are open to participants now.

Browse Virus Diseases studies →

Open to participants now

None of the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases is open now. The open studies under Virus Diseases, anywhere →

About mRNA-1345 respiratory syncytial virus vaccine

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 63 Virus Diseases studies recruiting now, 29 (46%) set no upper age limit and 22 (35%) stop at 75 or younger; 27 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing mRNA-1345 respiratory syncytial virus vaccine in Virus Diseases as a file.
02

Study summary

The study is divided into 2 parts (Part A and Part B). Part A of the study will evaluate the safety and immune response to mRNA-1345 in high-risk adults aged ≥18 to \<60 years.

Part B of the study will evaluate the safety and immune response to mRNA-1345 in adults who received solid organ transplant (SOT).

03

Conditions studied

  • Respiratory Syncytial Virus

Browse trials for

Keywords

  • Viral Diseases
  • Messenger RNA
  • Moderna
  • mRNA-1345
  • Respiratory syncytial virus
  • Safety
  • Vaccines
  • Immunocompromised
  • Organ transplant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

Part A:

  • Adults ≥18 to \<60 years of age at the time of consent who are primarily responsible for self-care and activities of daily living.
  • Documented confirmation by a physician of the diagnosis of at least one of the following conditions:

    1. Coronary artery disease and/or congestive heart failure.
    2. Chronic lung disease (for example, including but not limited to or persistent asthma).
    3. Stable type 1 or type 2 diabetes mellitus controlled with at least 1 medication started 90 days or more prior to Day 1.

Part B:

  • Adults ≥18 years of age at the time of consent who are primarily responsible for self-care and activities of daily living.
  • Recipient of an SOT (kidney, liver, or lung transplant) ≥180 days prior to day of consent and receiving chronic therapy for the prevention of allograft rejection.

Parts A and B:

- Able to comply with study requirements.

Key Exclusion Criteria:

Part A:

  • Participation in an another clinical research trial where the participant has received an product 180 days prior to Day 1. Participation in an RSV trial at any time prior to Day 1 is exclusionary.
  • History of a diagnosis or condition, that, in the judgment of the Investigator, is clinically unstable or may affect participant safety, assessment of safety endpoints, assessment of immune response, or adherence to study procedures.
  • Reported history of anaphylaxis or severe reaction after receipt of the mRNA-1345 injection or any components of the mRNA-1345 injection.
  • Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 180 days prior to Day 1.
  • History of myocarditis, pericarditis, or myopericarditis.

Part B:

  • Previous treatment with alemtuzumab or rituximab within 2 years prior to Day 1.
  • Previous treatment with plasmapheresis within 30 days prior to Day 1.
  • A history of complications of immunosuppression.
  • A history of proven or clinically diagnosed rejection within 90 days prior to Day 1 or suspected active chronic rejection according to the Investigator's judgment.

Note: Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,153 participants (actual)

Study arms

  • Experimental
    Part A: mRNA-1345 Dose 1

    Single injection of mRNA-1345 administered intramuscularly (IM) on Day 1.

    Biological: mRNA-1345

  • Experimental
    Part A: mRNA-1345 Dose 2

    Single injection of mRNA-1345 administered IM on Day 1.

    Biological: mRNA-1345

  • Experimental
    Part B: mRNA-1345 Dose 2

    Two injections of mRNA-1345 administered IM on Day 1 and Day 57.

    Biological: mRNA-1345

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs)

    Time frame: Day 1 through Day 7 (7 days post injection) for Part A and Day 1 through Day 64 (7 days post second injection) for Part B

  2. Number of Participants with Unsolicited Adverse Events (AEs)

    Time frame: Day 1 through Day 28 (28 days post injection) for Part A and Day 1 through Day 84 (28 days post second injection) for Part B

  3. Number of Participants With Medically Attended AEs (MAAEs)

    Time frame: Day 1 through Month 6 (for Part A) and Day 1 through Month 9 (for Part B)

  4. Number of Participants With Serious Adverse Events (SAEs), Adverse Events of Special Interest (AESIs), and AEs Leading to Discontinuation

    Time frame: Day 1 through End of Study (Day 730)

  5. Part A: Geometric Mean Titer (GMT) of Serum Respiratory Syncytial Virus Subtype A (RSV-A) and Respiratory Syncytial Virus Subtype B (RSV-B) Neutralizing Antibodies (Abs) at Day 29

    Time frame: Day 29

  6. Part B: GMT of Serum RSV-A and RSV-B Neutralizing Abs at Day 85

    Time frame: Day 85

Secondary outcomes

  1. Part A: Seroresponse Rate (SRR) of RSV-A and RSV-B Neutralizing Abs on Day 29

    Time frame: Day 29

  2. Part A: Geometric Mean Concentration (GMC) of Serum RSV Prefusion Conformation of the F Protein (Pre-F) Binding Abs

    Time frame: Up to End of Study (Day 730)

  3. Part A: Geometric Mean Fold-Rise (GMFR) of Serum RSV Pre-F Binding Abs

    Time frame: Up to End of Study (Day 730)

  4. Part A: SRR of Serum RSV Pre-F Binding Abs at Postbaseline/Baseline Levels

    Time frame: Baseline up to Day 730

  5. Part A: Number of Participants with ≥2-Fold Increase in RSV Pre-F Binding Abs

    Time frame: Up to End of Study (Day 730)

  6. Part A: GMT of Serum RSV-A and RSV-B Neutralizing Abs at Day 29

    Time frame: Day 29

  7. Part A: GMT of Postinjection/Baseline Titers to RSV-A and RSV-B Neutralizing Abs

    Time frame: Baseline up to Day 730

  8. Part A: GMFR of Postinjection/Baseline Titers to RSV-A and RSV-B Neutralizing Abs

    Time frame: Baseline up to Day 730

  9. Part A: SRR of Serum RSV-A and RSV-B Neutralizing Abs

    Time frame: Up to End of Study (Day 730)

  10. Part A: Number of Participants with ≥2-Fold Increase in RSV-A and RSV-B Neutralizing Abs Titers

    Time frame: Up to End of Study (Day 730)

  11. Part B: GMT of Serum RSV-A and RSV-B Neutralizing Abs at Day 29

    Time frame: Day 29

  12. Part B: SRR of Serum RSV-A and RSV-B Neutralizing Abs on Day 29

    Time frame: Day 29

  13. Part B: SRR of Serum RSV-A and RSV-B Neutralizing Abs on Day 85

    Time frame: Day 85

  14. Part B: GMT of Serum RSV-A and RSV-B Neutralizing Abs

    Time frame: Up to End of Study (Day 730)

  15. Part B: GMFR of Serum RSV-A and RSV-B Neutralizing Abs

    Time frame: Up to End of Study (Day 730)

  16. Part B: SRR of Serum RSV-A and RSV-B Neutralizing Abs at Postbaseline/Baseline Levels

    Time frame: Baseline up to Day 730

  17. Part B: Number of Participants with ≥2-Fold Increase in RSV-A and RSV-B Neutralizing Abs

    Time frame: Up to End of Study (Day 730)

  18. Part B: GMC of Serum RSV Pre-F Binding Abs

    Time frame: Up to End of Study (Day 730)

  19. Part B: GMFR of Serum RSV Pre-F Binding Abs

    Time frame: Up to End of Study (Day 730)

  20. Part B: SRR of Serum RSV Pre-F Binding Abs at Postbaseline/Baseline Levels

    Time frame: Baseline up to End of Study (Day 730)

  21. Part B: Number of Participants with ≥2-Fold Increase in RSV Pre-F Binding Abs

    Time frame: Up to End of Study (Day 730)

07

Study locations

44 sites
  • Lenzmeier Family Medicine - CCT - PPDS
    Glendale, Arizona 85308-5093, United States
  • Foothills Research Center - CCT - PPDS
    Phoenix, Arizona 85044-6097, United States
  • Fiel Family & Sports Medicine - PC - CCT - PPDS
    Tempe, Arizona 85283-1528, United States
  • Baptist Health Center for Clinical Research
    Little Rock, Arkansas 72205, United States
  • David Geffen School of Medicine at UCLA
    Los Angeles, California 90095-3075, United States
  • Artemis Institute For Clinical Research LLC - San Diego - Headlands - PPDS
    San Diego, California 92103-2209, United States
  • Critical Care, Pulmonary and Sleep Associates / CCT Research
    Lakewood, Colorado 80228, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06510-2483, United States
  • Excel Medical Clinical Trials DBA Flourish
    Boca Raton, Florida 33434, United States
  • Indago Research and Health Center
    Hialeah, Florida 33012-4170, United States
  • CenExel RCA - Hollywood
    Hollywood, Florida 33024-2709, United States
  • Clinical Research Atlanta - Headlands - PPDS
    Stockbridge, Georgia 30281-9054, United States
  • Snake River Research, PLLC
    Idaho Falls, Idaho 83404-7573, United States
  • University of Chicago
    Chicago, Illinois 60637-1443, United States
  • AES - DRS - Optimal Research Illinois - Peoria
    Peoria, Illinois 61614-4885, United States
  • Benchmark Research - Covington - HyperCore - PPDS
    Covington, Louisiana 70433, United States
  • Velocity Clinical Research (Rockville - Maryland) - PPDS
    Rockville, Maryland 20854-2960, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202-2608, United States
  • DM Clinical Research - Southfield - ERN - PPDS
    Southfield, Michigan 48076-5412, United States
  • Velocity Clinical Research (Lincoln - Nebraska) - PPDS
    Lincoln, Nebraska 68510, United States
  • University of Rochester - Rochester General Hospital - PPDS
    Rochester, New York 14621-3011, United States
  • Montefiore Medical Center - BRANY - PPDS
    The Bronx, New York 10467-2401, United States
  • Duke University Medical Center
    Durham, North Carolina 27710, United States
  • DM Clinical Research - Philadelphia - ERN - PPDS
    Philadelphia, Pennsylvania 19107-1530, United States
  • Benchmark Research - Fort Worth - HyperCore - PPDS
    Fort Worth, Texas 76135-5283, United States
  • DM Clinical Research - Cyfair Clinical Research Center
    Houston, Texas 77065-5685, United States
  • Benchmark Research - San Angelo - HyperCore - PPDS
    San Angelo, Texas 76904-7610, United States
  • DM Clinical Research - ERN - PPDS
    Tomball, Texas 77375-6543, United States
  • Springville Dermatology - CCT - PPDS
    Springville, Utah 84663, United States
  • Velocity Clinical Research - Hampton - PPDS
    Hampton, Virginia 23666-6262, United States
  • Centricity Research Suffolk Family Medicine
    Suffolk, Virginia 23435-3763, United States
  • Velocity Clinical Research - Family Practice - Suffolk - PPDS
    Suffolk, Virginia 23435, United States
  • University of Alberta
    Edmonton, Alberta T6G 2B7, Canada
  • OCT Research ULC (dba Okanagan Clinical Trials)
    Kelowna, British Columbia V1Y 1Z9, Canada
  • Canadian Center for Vaccinology
    Halifax, Nova Scotia L7 8XZ, Canada
  • Colchester Research Group
    Truro, Nova Scotia B2N 1L2, Canada
  • Diex Recherche - Sherbrooke - PPDS
    Sherbrooke, Quebec J1L 0H8, Canada
  • Diex Recherche - Québec - PPDS
    Québec, G1V 4T3, Canada
  • Caribbean Medical Research Center
    San Juan, 00918, Puerto Rico
  • Royal Devon and Exeter Hospital
    Exeter, Devon EX2 5DW, United Kingdom
  • Fylde Coast Clinical Research
    Blackpool, Lancashire FY3 7EN, United Kingdom
  • Liverpool School of Tropical Medicine
    Liverpool, Merseyside L7 8XZ, United Kingdom
  • Aberdeen Royal Infirmary - PPDS
    Aberdeen, AB25 2ZD, United Kingdom
  • The Royal Free Hospital
    London, NW3 2QG, United Kingdom
08

References and documents

Publications

  • Mayer EF, Falsey AR, Wolfe CR, Herc E, Burns F, Kabbani D, Kumar D, Mannan A, She F, Lan L, McGrath S, Kapoor A, Priddy F. Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345. Clin Infect Dis. 2026 May 20;82(5):e1112-e1121. doi: 10.1093/cid/ciag108. PubMed 41711453 ↗
  • Mayer EF, Falsey AR, Clark R, Ferguson M, Cardona J, She F, Jones B, Reuter C, Collins A, Mannan A, Kapoor A, Slobod K, Stoszek SK, Du J, Mou J, Lan L, Zhou H, Wilson E, Goswami J, Das R, Priddy F. Safety, Tolerability, and Immunogenicity of mRNA-1345 in Adults at Increased Risk for Respiratory Syncytial Virus Disease Aged 18-59 Years. Clin Infect Dis. 2026 Feb 4;81(6):e708-e716. doi: 10.1093/cid/ciaf292. PubMed 40464662 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2023 to primary completion in Jul 2026, 33 months.

Of 40 industry-sponsored phase 3 interventional studies under Virus Diseases, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 24. This study's 33 months is above that.

Counting every sponsor, half of 57 studies reached it within 14 months; a quarter within 8 and three quarters within 24.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 4, 2023
StartActual
Oct 6, 2023
Primary completionActual
Jul 24, 2026
CompletionActual
Jul 24, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06067230
Lead sponsor
ModernaTX, Inc.
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Oct 6, 2023
Primary completion
Jul 24, 2026
Completion
Jul 24, 2026
Last update
Aug 20, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: mRNA-1345 respiratory syncytial virus vaccine

Start the discussion